Please select an option below to help us tailor your newsletter to best suit your content interests!
Colorectal, colon, rectum, rectal
Stage 4
Phase 2
Open to Enrollment
1st Line
Onvansertib
Polo-like kinase 1 inhibitor
Brad Somer, MD
Cardiff Oncology
Adenocarcinoma
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER
VIEW TRIAL ON CLINICALTRIALS.GOVColon cancer, rectal cancer, colorectal cancer
Stage 4
Phase 2
Open to Enrollment
1st Line
encorafenib, cetuximab, pembrolizumab
BRAF inhibitor, EGFR mAb, PD-1 inhibitor
Brad Somer, MD
Pfizer
BRAF V600 mutant, MSI-h, dMMR
AndroMETa-CRC-064 Abbvie M24-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Cancer
VIEW TRIAL ON CLINICALTRIALS.GOVColorectal, colon, rectum, rectal
Stage 4
Phase 3
Open to Enrollment
3rd or later
ABBV-400
Anti-cMET ADC
Axel Grothey, MD
Abbvie
Adenocarcinoma
A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial Cancer, Head and Neck Squamous cell carcinoma (HNSCC), Pancreatic cancer (PDAC), Colon Rectal Colorectal cancer (CRC), Hepatocellular carcinoma (HCC), Esophageal adenocarcinoma, gastroesophageal junction (GE junction), gastric, urothelial carcinoma (UC) bladder, ovarian cancer, cervical cancer, biliary tract cancer, HER2 low breast cancer, HER2 negative breast cancer, melanoma
Stage 4
Phase 2
Open to Enrollment
2nd line or later
I-DXd
B7-H3 antibody drug conjugate
Axel Grothey, MD
Daiichi Sankyo
See under \\\"malignancy\\\"